Comorbidity-Adjusted Life Expectancy: A New Tool to Inform Recommendations for Optimal Screening Strategies

2013 ◽  
Vol 159 (10) ◽  
pp. 667 ◽  
Author(s):  
Hyunsoon Cho ◽  
Carrie N. Klabunde ◽  
K. Robin Yabroff ◽  
Zhuoqiao Wang ◽  
Angela Meekins ◽  
...  

2012 ◽  
Vol 60 (4) ◽  
pp. 684-690 ◽  
Author(s):  
Susan L. Greenspan ◽  
Subashan Perera ◽  
David Nace ◽  
Kimberly S. Zukowski ◽  
Mary A. Ferchak ◽  
...  


2005 ◽  
Vol 20 (6) ◽  
pp. 487-496 ◽  
Author(s):  
Jeanne S. Mandelblatt ◽  
◽  
Clyde B. Schechter ◽  
K. Robin Yabroff ◽  
William Lawrence ◽  
...  


2020 ◽  
Vol 5 (1) ◽  
pp. 238146832093289
Author(s):  
Djøra I. Soeteman ◽  
Stephen C. Resch ◽  
Hawre Jalal ◽  
Caitlin M. Dugdale ◽  
Martina Penazzato ◽  
...  

Background. Metamodels can simplify complex health policy models and yield instantaneous results to inform policy decisions. We investigated the predictive validity of linear regression metamodels used to support a real-time decision-making tool that compares infant HIV testing/screening strategies. Methods. We developed linear regression metamodels of the Cost-Effectiveness of Preventing AIDS Complications Pediatric (CEPAC-P) microsimulation model used to predict life expectancy and lifetime HIV-related costs/person of two infant HIV testing/screening programs in South Africa. Metamodel performance was assessed with cross-validation and Bland-Altman plots, showing between-method differences in predicted outcomes against their means. Predictive validity was determined by the percentage of simulations in which the metamodels accurately predicted the strategy with the greatest net health benefit (NHB) as projected by the CEPAC-P model. We introduced a zone of indifference and investigated the width needed to produce between-method agreement in 95% of the simulations. We also calculated NHB losses from “wrong” decisions by the metamodel. Results. In cross-validation, linear regression metamodels accurately approximated CEPAC-P-projected outcomes. For life expectancy, Bland-Altman plots showed good agreement between CEPAC-P and the metamodel (within 1.1 life-months difference). For costs, 95% of between-method differences were within $65/person. The metamodels predicted the same optimal strategy as the CEPAC-P model in 87.7% of simulations, increasing to 95% with a zone of indifference of 0.24 life-months ( ∼ 7 days). The losses in health benefits due to “wrong” choices by the metamodel were modest (range: 0.0002–1.1 life-months). Conclusions. For this policy question, linear regression metamodels offered sufficient predictive validity for the optimal testing strategy as compared with the CEPAC-P model. Metamodels can simulate different scenarios in real time, based on sets of input parameters that can be depicted in a widely accessible decision-support tool.



2010 ◽  
Vol 58 (5) ◽  
pp. 1269-1286 ◽  
Author(s):  
Marion S. Rauner ◽  
Walter J. Gutjahr ◽  
Kurt Heidenberger ◽  
Joachim Wagner ◽  
Joseph Pasia


2021 ◽  
Vol 18 (180) ◽  
pp. 20210164
Author(s):  
Jordan P. Skittrall

Testing asymptomatic people for SARS-CoV-2 aims to reduce COVID-19 transmission. Screening programmes’ effectiveness depends upon testing strategy, sample handling logistics, test sensitivity and individual behaviour, in addition to dynamics of viral transmission. The interaction between these factors is not fully characterized. We investigated the interaction between these factors to determine how to optimize reduction of transmission. We estimate that under idealistic assumptions 70% of transmission may be averted, but under realistic assumptions only 7% may be averted. We show that programmes that overwhelm laboratory capacity or reduce isolation of those with minor symptoms have increased transmission compared with those that do not: programmes need to be designed to avoid these issues, or they will be ineffective or even counter-productive. Our model allows optimal selection of whom to test, quantifies the balance between accuracy and timeliness, and quantifies potential impacts of behavioural interventions. We anticipate our model can be used to understand optimal screening strategies for other infectious diseases with substantially different dynamics.





2014 ◽  
Vol 100 (6) ◽  
pp. S339-S347 ◽  
Author(s):  
P. Wicart ◽  
A. Bocquet ◽  
N. Gelbert ◽  
G. Beley ◽  
R. Proslier ◽  
...  


Cureus ◽  
2018 ◽  
Author(s):  
Wasique Mirza ◽  
Muhammad Sabih Saleem ◽  
Gaurav Patel ◽  
Pravin Chacko ◽  
Sandhya Reddy ◽  
...  


2007 ◽  
Vol 177 (4S) ◽  
pp. 77-77
Author(s):  
Patti Groome ◽  
D. Robert Siemens ◽  
William J. MacKillop ◽  
Michael Brundage ◽  
Jun Kawakami ◽  
...  


2007 ◽  
Vol 177 (4S) ◽  
pp. 131-132 ◽  
Author(s):  
Jochen Wafz ◽  
Andrea Gallina ◽  
Aldo M. Bocciardi ◽  
Sascha Ahyai ◽  
Paul Perrotta ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document